199 related articles for article (PubMed ID: 32083752)
1. Systematic use of fluorescence in-situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms.
Fang H; Tang G; Loghavi S; Greipp P; Wang W; Verstovsek S; Medeiros LJ; Reichard KK; Miranda RN; Wang SA
Histopathology; 2020 Jun; 76(7):1042-1054. PubMed ID: 32083752
[TBL] [Abstract][Full Text] [Related]
2. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
Jawhar M; Naumann N; Schwaab J; Baurmann H; Casper J; Dang TA; Dietze L; Döhner K; Hänel A; Lathan B; Link H; Lotfi S; Maywald O; Mielke S; Müller L; Platzbecker U; Prümmer O; Thomssen H; Töpelt K; Panse J; Vieler T; Hofmann WK; Haferlach T; Haferlach C; Fabarius A; Hochhaus A; Cross NCP; Reiter A; Metzgeroth G
Ann Hematol; 2017 Sep; 96(9):1463-1470. PubMed ID: 28725989
[TBL] [Abstract][Full Text] [Related]
3. [Pediatric myeloid neoplasms associated with eosinophilia and platelet-derived growth factor receptor beta gene rearrangement: a case report and literature review].
Zhang XY; Liu TF; Li CW; Li QH; Zhu XF
Zhonghua Er Ke Za Zhi; 2018 Jan; 56(1):34-38. PubMed ID: 29342995
[No Abstract] [Full Text] [Related]
4. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
Pozdnyakova O; Orazi A; Kelemen K; King R; Reichard KK; Craig FE; Quintanilla-Martinez L; Rimsza L; George TI; Horny HP; Wang SA
Am J Clin Pathol; 2021 Feb; 155(2):160-178. PubMed ID: 33367495
[TBL] [Abstract][Full Text] [Related]
5. Myeloid neoplasm with a novel cryptic PDGFRB rearrangement detected by next-generation sequencing.
Zimmermann N; Nassiri M; Zhou J; Miller AM; Zhang S
Cancer Genet; 2020 Jun; 244():55-59. PubMed ID: 32442889
[TBL] [Abstract][Full Text] [Related]
6. Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene.
Yamazaki M; Nakaseko C; Takeuchi M; Ozawa S; Ishizuka Y; Hatanaka Y; Oshima-Hasegawa N; Muto T; Tsukamoto S; Mitsukawa S; Ohwada C; Takeda Y; Mimura N; Iseki T; Fukazawa M; Sakaida E
Intern Med; 2019 Dec; 58(23):3449-3453. PubMed ID: 31327842
[TBL] [Abstract][Full Text] [Related]
7. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
[TBL] [Abstract][Full Text] [Related]
8. Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement.
Di Giacomo D; Quintini M; Pierini V; Pellanera F; La Starza R; Gorello P; Matteucci C; Crescenzi B; Fiumara PF; Veltroni M; Borlenghi E; Albano F; Forghieri F; Maccaferri M; Bettelli F; Luppi M; Cuneo A; Rossi G; Mecucci C
Ann Hematol; 2022 Feb; 101(2):297-307. PubMed ID: 34859285
[TBL] [Abstract][Full Text] [Related]
9. Myeloid Neoplasm with PCM1-PDGFRB Transcript Responded to Low-Dose Imatinib: One Case Report with Literature Review.
Wang Z; Wan L; Lin D; Li CW; Tian Z; Mi YC
Acta Haematol; 2022; 145(5):560-565. PubMed ID: 35340014
[TBL] [Abstract][Full Text] [Related]
10. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.
Arefi M; García JL; Peñarrubia MJ; Queizán JA; Hermosín L; López-Corral L; Megido M; Giraldo P; de las Heras N; Vanegas RJ; Gutiérrez NC; Hernández-Rivas JM
Eur J Haematol; 2012 Jul; 89(1):37-41. PubMed ID: 22587685
[TBL] [Abstract][Full Text] [Related]
11. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
Savage N; George TI; Gotlib J
Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia.
Xu X; Lu Q; Wang Z; Cai P; Zeng Z; Zhang L; Wang M; Ma L; Ruan C; Chen S
Cancer Res Treat; 2021 Jul; 53(3):889-892. PubMed ID: 33421986
[TBL] [Abstract][Full Text] [Related]
13. [Heterogenous abnormality polymorphism of gene PDGFRB in myeloid neoplasms and its clinical characteristics].
Wang QS; Gao L; Jing Y; Zhu HY; Yang H; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):291-5. PubMed ID: 22541084
[TBL] [Abstract][Full Text] [Related]
14. [Myeloid neoplasms associated with rearrangement of PDGFRB: A rare and tricky disease].
Bontoux C; Badaoui B; Abermil N; Tarfi S; Guermouche H; Dubois S; Roy L; Xuan JV; Quang VT; Wang L; Favre L; Poullot E; Michel M; Sloma I; Crickx E; Pécriaux A
Ann Pathol; 2022 Nov; 42(6):481-487. PubMed ID: 36050197
[TBL] [Abstract][Full Text] [Related]
15. Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate.
Zou YS; Hoppman NL; Singh ZN; Sawhney S; Kotiah SD; Baer MR
Cancer Genet; 2017 Apr; 212-213():38-44. PubMed ID: 28449810
[TBL] [Abstract][Full Text] [Related]
16. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
[TBL] [Abstract][Full Text] [Related]
17. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
[TBL] [Abstract][Full Text] [Related]
18. Multiple
Sheng G; Zeng Z; Pan J; Kou L; Wang Q; Yao H; Wen L; Ma L; Wu D; Qiu H; Chen S
Mol Cytogenet; 2017; 10():4. PubMed ID: 28261327
[TBL] [Abstract][Full Text] [Related]
19. A novel subclonal rearrangement of the STRN3::PDGFRB gene in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects.
Wang Z; Liu T; Liu W; Gao X; Wan L; Qiu S; Song Y; Gu R; Tian Z; Wang M; Wang J; Mi Y; Wei S
Cancer Gene Ther; 2023 Nov; 30(11):1471-1484. PubMed ID: 37550570
[TBL] [Abstract][Full Text] [Related]
20. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
